Erenumab in Highly Therapy-refractory Migraine Patients: First Real-world Evidence

CURRENT STATUS: UNDER REVIEW

The Journal of Headache and Pain | BMC

Armin Scheffler
University of Duisburg-Essen, University Hospital Essen, Department of Neurology

Olga Messel
University of Duisburg-Essen

Sebastian Wurthmann
University of Duisburg-Essen, University Hospital Essen, Department of Neurology

Michael Nsaka
University of Duisburg-Essen, University Hospital Essen, Department of Neurology

Christoph Kleinschnitz
University of Duisburg-Essen, University Hospital Essen, Department of Neurology

Martin Glas
University of Duisburg-Essen, University Hospital Essen, Department of Neurology

Steffen Naegel
Martin Luther University Halle-Wittenberg, University Hospital Halle, Department of Neurology

Dagny Holle-Lee
University of Duisburg-Essen, University Hospital Essen

Corresponding Author
Dagny.Holle-Lee@uk-essen.de
ORCiD: https://orcid.org/0000-0003-4872-0384

DOI: 10.21203/rs.3.rs-19814/v1

SUBJECT AREAS
Anesthesiology & Pain Medicine

KEYWORDS
migraine, erenumab, therapy, real-world, CGRP antibody
Abstract

**Background:** Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAB) are the first specific migraine prophylactic medication. Erenumab is the only CGRP mAB targeting the CGRP receptor. Clinical data regarding efficacy and tolerability of erenumab in highly therapy-refractory patients are not available, yet, although many patients treated with CGRP mAB under real world conditions can be considered as highly therapy-refractory.

**Methods:** Clinical routine data of highly therapy-refractory migraine patients treated with erenumab 70mg for three months between November 2018 and December 2019 in the West German Headache Center, University Hospital Essen, Germany, were analysed. Monthly migraine days (MMD), monthly headache days (MHD) and days of acute medication intake (AMD) were assessed. Statistical analysis was performed using the Wilcoxon test. Descriptive statistics were performed to evaluate changes of vegetative symptoms, acute medication response, side effects, as well as treatment satisfaction.

**Results:** Complete clinical data were available for 26 episodic (EM) and 74 chronic (CM) migraineurs. Sixty-six % (n=49) of CM patients had an additional medication overuse headache (MOH). After three months 57.7 % of EM patients and 41.9 % of CM patients had a 50% or greater reduction of MMD. The mean number of MMD was reduced by 3.43 (SE 1.26) in EM, and by 4.72 (SE 0.87) in CM. Thirty-nine patients (52.7%) returned from chronic to episodic course of migraine. After three months, 23 patients (46.9%) were not suffering from a MOH anymore.

**Conclusions:** Erenumab seems to be a promising therapeutic option in highly therapy-refractory migraine patients.

**Background**

Migraine is the 3rd most prevalent illness in the world and one of the main causes of disability. So far available non-specific prophylactic drug medication was often poorly tolerated and not effective in every patient. Recently, monoclonal CGRP (calcitonin gene related peptide) antibodies (mAB) have become the first specific migraine prophylaxis, which has shown its efficacy in large phase III studies in the treatment of episodic (EM) and chronic migraine (CM) with or without medication overuse headache (MOH) and is now available worldwide for migraine treatment.
In Europe, three CGRP mAB, erenumab (Aimovig®, Novartis, Basel, Switzerland), fremanezumab (Ajovy®, Teva, Petach Tikva, Israel) and galcanezumab (Emgality®, Lilly, Indianapolis, USA) are approved for migraine prevention in patients suffering from at least four migraine days per month. Erenumab is the only substance targeting the CGRP receptor instead of the molecule itself. Thus far, no clear differences in efficacy and tolerability between the individual mABs could be identified. Clinical trials were only performed in migraine patients who had failed up to four prophylactic medications in the past.\textsuperscript{2–4} Data on highly therapy-refractory patients that had failed more than four prophylactic treatments are missing, yet.

We present for the first time clinical data on this highly therapy-refractory migraine population treated with erenumab under real world conditions.

Methods

We retrospectively analysed routine clinical data of EM and CM patients presented at the West German Headache Center, Department of Neurology, University Hospital Essen, Germany between November 2018 and December 2019. The analysis was approved by the independent ethics committee of the University Hospital Essen. Patients meeting the following criteria were included in the analysis: a) EM/CM patients with at least 4 migraine days a month according to the current diagnostic criteria of the International headache classification (ICHD-3\textsuperscript{5}), b) documented history of the last three months prior starting erenumab therapy regarding monthly migraine days (MMD), monthly headache days (MHD), and monthly intake of acute medication (AMD), c) completion of a three-month treatment interval with monthly 70mg erenumab, d) available complete clinical data including headache diaries and questionnaires regarding medication related side effects, change of migraine associated symptoms over the treatment period and treatment satisfaction. Due to reasons of reimbursement by the German statutory health insurance, all treated patients had tried at least 5 (when EM) and 6 (when CM) approved prophylactic drug classes previously without sufficient treatment effects, had discontinued those due to side effects, or were not eligible for intake due to contraindication. Approved drug classes were the following: betablockers (metoprolol, propranolol), amitriptyline, flunarizine, topiramate, valproic acid and for CM additionally onabotulinumtoxin A.
Data were analysed using SPSS software (IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp). Wilcoxon`s test was used to compare MMD, MHD, and AMD before and after treatment. The test procedure was two-sided, Bonferoni`s method for multiple comparisons was set at $p<0.05/3 = 0.016$. Patient reported outcomes were reported descriptively.

Results
Clinical data of a total of 100 migraine patients were analysed. Details regarding demographic data and numbers of MMD, MHD, and AMD before and after treatment are stated in table 1. In brief, most of the patients were female (82%; n=82), 26% (n=26) suffered from EM, 74% (n=74) from CM. Sixty-six % (n=49) of CM patients had an additional MOH. (Table 1 here)

After 3 months of erenumab therapy 57.7 % of EM patients (n=15) and 41.9 % of CM patients (n=31) had at least a 50% reduction in MMD (Fig.1). Fifty-three % of patients (n=39) returned from chronic to episodic course of migraine. After three months, 46.9% of patients (n=23) were not suffering from MOH anymore.
Subjective improvement of migraine intensity and duration was reported by considerably more than half of the patients (n=95, 70.5% and n=90, 58.9%, respectively). Subjective treatment effects on migraine associated vegetative symptoms were rather small. Efficacy of acute medication was largely unchanged under therapy (Fig.2).
Self-reported general satisfaction with therapy was high (very satisfactory/satisfactory 61,3% (n=57); moderately satisfactory 20,4% (n=19); unsatisfactory/very unsatisfactory 18,3% (n=17)).
Side effects were reported by 42% (n=42) of patients, mainly digestive problems or constipation (15%, n=10), injection side skin symptoms or itching (15%; n=10), fatigue or a feeling of exhaustion (10%, n=7), and insomnia (6%, n=4). One patient discontinued treatment due to severe constipation.

Discussion
Our clinical data show for the first time efficacy and tolerability of CGRP mAB under real world conditions. Data on this highly therapy-refractory patient population were not available, yet. The results of our analysis look very promising, especially considering the fact that no other approved drug therapies have been available for this patient population.
Efficacy of erenumab in highly therapy-refractory patients is comparable to results from clinical trials of patients that had failed fewer prophylactic medications prior treatment. Under trial conditions migraine days went down between 1.8 and 3.7 days/month \(^{2,6,7}\) compared to a reduction of 3.43 days/month in EM under real world conditions; MMD 50% responder rates were between 30% and 43.3% \(^{2,6,7}\) compared to 57.7% in this real-world analysis. Results from the phase II erenumab CM trial reported a reduction of 6.6 days/month and a 50% responder rate of 40% \(^{8}\) which is comparable to our real world data showing a reduction of 4.72 days and a 50% responder rate of 41.9%.

Compared to the clinical studies, similarly high rates of side effects were found and no serious side effects occurred\(^{2,6,9}\) supporting a good tolerability of erenumab.

Many patients with highly therapy-refractory migraine suffer from additional MOH, in our real-world population 49% of all analysed patients. Our data show that erenumab could also be effective in patients with additional MOH although medication overuse was not stopped prior therapy. Our observations confirm the data of the subgroup analysis of the CM Phase II erenumab study \(^{9}\), also showing the efficacy of erenumab in MOH.

Besides reduction of frequency and acute medication intake, the greatest therapeutic effect was seen in reduction of intensity and duration of migraine attacks. The therapeutic effect of erenumab seems to be less pronounced regarding vegetative accompanying symptoms of migraine. For the majority of our patients, migraine-associated phonophobia, photophobia and nausea remained unchanged. It can only be assumed that vegetative accompanying symptoms are mainly driven by central mechanisms and therefore less influenced by the peripheral acting CGRP antibody whereas migraine pain intensity and frequency might be more peripherally modulated.

Shortcoming of this single-center experience are mainly its retrospective nature and that data are mainly based on purely subjective reports of patients. Nevertheless, these data are important from our point of view, as better evaluations regarding headache of this predominantly treated patient collective are still missing. Additionally, patients in our patient population received the lower erenumab dosage of 70mg instead of the now available 140mg dosage. There is some evidence that
difficult-to-treat patients who failed prophylactic medication in the past may benefit more from 140mg compared to 70mg erenumab\(^\text{10}\). However, there are no data of direct comparison between 70 and 140mg dosage. Whether patients could benefit more from a higher dosage cannot be answered at present.

**Conclusion**

Our data show that erenumab is a promising therapy option in highly therapy-refractory migraine patients with or without MOH. Real-world efficacy and tolerability of erenumab seems to be comparable with results from clinical trials, even in more therapy-refractory than patients treated in clinical studies. Future applications will show whether our results can be confirmed for larger numbers of patients and for CGRP mAB in general.

**Abbreviations**

AMD: Monthly intake of acute medication; CGRP: Calcitonin gene related peptide; CM: Chronic migraine; EM: Episodic migraine; ICHD-3: International headache classification; mAB: monoclonal antibody; MHD: Monthly headache days; MMD: Monthly migraine days; MOH: Medication overuse headache; SE: Standard error

**Declarations**

**Acknowledgements:**

Benjamin Kubo corrected the manuscript regarding language. The study is part of the doctor thesis of one of the authors (OM).

**Ethics approval and consent to participate:**

The analysis was approved by the independent ethics committee of the University Hospital Essen (19-9004-BO) and all patients gave written consent to general analysis of their personal and clinical data.

**Consent for publication:**

Not applicable

**Availability of data and materials:**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:**
AS received travel fees from Teva, honoraria for participation on an advisory board of Novartis. SW reports personal fees from Allergan, personal fees from Tea, personal fees from Novartis, outside the submitted work. MG received honoraria from Novartis, UCB, Teva, Bayer, Novocure, Medac, Merck, Kyowa Kirin, has a consulting or advisory role to declare for Roche, Novartis, AbbVie, Novocure, and Daiichi Synkyo, and received travel fees from Novocure and Medac. SN reports grants from Novartis, personal fees from Novartis, personal fees from Novartis, personal fees from Teva, outside the submitted work. DH has received scientific support and/or honoraria from Biogen, Novartis, Lilly, Sanofi-Aventis, Teva, Allergan, Hormosan. OM, MN and CK declare that they have no competing interests.

**Funding:**

No funding

**Authors' contributions:**

AS has the major role in the acquisition of data, analysed and interpreted the data and drafted the manuscript for intellectual content. OM analysed and interpreted the data and revised the manuscript for intellectual content. SW, MN, CK, SN and MG interpreted the data and revised the manuscript for intellectual content. DH designed and conceptualized study, interpreted the data and drafted the manuscript for intellectual content. All authors read and approved the final manuscript.

**References**

1. GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:459-480.

2. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet Lond Engl. 2018;392:2280-2287.

3. Ferrari MD, Diener HC, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive
medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Lond Engl. 2019;394:1030-1040.

4. Mulleners W, Kim B, Láinez MJ, et al. A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study. J Neurol Sci. 2019;405:128.

5. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.

6. Goadsby PJ, Reuter U, Hallström Y, et al. A Controlled Trial of Erenumab for Episodic Migraine. N Engl J Med. 2017;377:2123-2132.

7. Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia Int J Headache. 2018;38:1026-1037.

8. Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16:425-434.

9. Tepper SJ, Diener H-C, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019;92:e2309-e2320.

10. Ornello R, Tiseo C, Frattale I, et al. The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain [online serial]. 2019;20. Accessed at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822439/. Accessed December 26, 2019.

Table 1: Patients' characteristics and treatment response: Data before treatment reflect the 3
months before start of erenumab treatment. (MMD: monthly migraine days; MHD: monthly headache days; AMD: monthly days of intake of acute migraine medication; SD: standard deviation; SE: standard error; y: years; d: days)

| A) Episodic migraine (n=26) |
|-----------------------------|
| Age, y                      | 52.9 (SD 9.1) |
| Sex, female : male          |               |

|                      | Before treatment, d | After 3 month, d | P-value | Change from baseline |
|----------------------|---------------------|------------------|---------|----------------------|
| MMD (SD)             | 9.42 (2.91)         | 5.99 (5.43)      | < 0.001 | -3.43 (SE 1.26)      |
| MHD (SD)             | 10.40 (2.47)        | 7.06 (5.46)      | 0.001   | -3.33 (SE 1.17)      |
| AMD (SD)             | 10.22 (4.69)        | 5.74 (5.07)      | <0.001  | -4.48 (SE 1.27)      |

| B) Chronic migraine (n=74) |
|---------------------------|
| Age, y                    | 45.8 (SD 12.9)      |
| MOH (before treatment), n | 49                  |
| MOH (after 3 month), n    |                     |

|                      | Before treatment, d | After 3 month, d | P-value | Change from baseline |
|----------------------|---------------------|------------------|---------|----------------------|
| MMD (SD)             | 15.69 (6.64)        | 10.97 (7.81)     | <0.001  | -4.72 (SE 0.87)      |
| MHD (SD)             | 21.27 (5.5)         | 15.8 (8.9)       | <0.001  | -5.47 (SE 0.86)      |
| AMD (SD)             | 11.62 (6.14)        | 8.86 (5.97)      | <0.001  | -2.76 (SE 0.83)      |

Figures
Figure 1

Therapy response after 3 months of erenumab treatment. Number of monthly migraine days before and after three months of treatment with erenumab. Every plotting symbol represents a patient with EM (circle) or CM (triangle). All symbols on the function $y = 0.5x$ and below show a reduction of at least 50%. The symbols below the function $y = x$ represent patients who still have less monthly migraine days after 3 months of treatment, all symbols on the function or above can be considered as non-responder.
Figure 2

Distinct treatment responses regarding migraine characteristics Patient reported subjective treatment response after three months of erenumab therapy. Migraine-associated vegetative symptoms, dizziness, need for rest and effects of acute medications stayed unaffected in the majority of patient, while duration and intensity of migraine improved.